

## **A Review of Bleeding Risk with Impella-supported High-risk Percutaneous Coronary Intervention**

George W. Vetrovec, MD<sup>1</sup>, Amir Kaki, MD<sup>2</sup> and Thom G. Dahle, MD<sup>3</sup>

1. VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA
2. Division of Cardiology, St. John's Hospital, Wayne State University, Detroit, MI, USA
3. Centracare Heart & Vascular Center, St. Cloud Hospital, St. Cloud, MN, USA

**Corresponding Author:** George W. Vetrovec, MD, MACC, MSCAI, 3126 W. Cary St. #693, Richmond, VA 23221-3504 USA. E: [gvetrovec@gmail.com](mailto:gvetrovec@gmail.com)

### **Acknowledgements**

Dana Bentley, MWC, assisted with the literature review and provided medical writing services, funded by the device manufacturer and in accordance with GPP3.

### **Author disclosures / conflicts of interest:**

George Vetrovec has acted as a consultant for Abiomed, Merck and the FDA. Amir Kaki has acted as a proctor and speaker for Abiomed. Thom G Dahle has acted as a proctor and consultant for Abiomed.

**Review Process:** Double-blind peer review

**Compliance with Ethics:** This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

**Authorship:** All named authors meet the criteria of the International Committee of Medical Journal Editors for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.

**Access:** This article is freely accessible at touchCARDIO.com © Touch Medical Media 2020

**Received:** 27 October 2020

**Accepted:** 29 December 2020

**Published Online:** 29 December 2020

**Citation:** *Heart International*. 2020;14(2):Online ahead of journal publication

**Support:** No funding was received in the publication of this article.

**\*\*This manuscript has been accepted for publication, but not yet copyedited or typeset, and may be subject to minor changes during the production process\*\***

**Abstract**

Complex, high-risk percutaneous coronary intervention (HR-PCI) is increasingly being performed, often with mechanical circulatory support (MCS), though to date, there is limited randomized data on the efficacy of MCS for HR-PCI. The majority of MCS is provided by intra-aortic balloon pumps (IABP), but increasingly Impella heart pumps are being used. While the Impella pumps provide greater increases in cardiac output, these devices require large bore access, which has been associated with an increased risk of bleeding and vascular complications. Decisions regarding the use of Impella are often based on risk-benefit considerations, with Impella-related bleeding risk being a major factor that can impact decisions for planned use. While bleeding risk related to large bore access is a concern, published data on the risk has been quite variable. Thus, the goal of this article is to provide a comprehensive review of reports describing bleeding and vascular complications for Impella-supported HR-PCI.

**Keywords:** High-risk percutaneous coronary intervention (PCI), haemodynamic support, PCI bleeding complications, mechanical circulatory support, PCI vascular complications, percutaneous left ventricular assist device (pVAD)

Percutaneous coronary intervention (PCI) has evolved over recent years, with increasingly more complex, high-risk procedures being performed, including patients with multivessel coronary artery disease (CAD) with or without left main (LM) disease, often complicated by severe left ventricular (LV) dysfunction.<sup>1</sup> In addition, decisions about coronary bypass surgery (CABG) or PCI often focus not only on coronary anatomy, but also on clinical factors including renal impairment, age, and body mass index (BMI), as well as patient wishes. For many patients considered poor candidates for CABG due to significant comorbidities, PCI represents an appropriate alternative.

A recent analysis found that 21.5% of potential CABG patients were deemed ineligible for surgery and underwent PCI.<sup>2</sup> PCI for such patients (often with impaired LV function) involves an elevated risk for circulatory collapse during the procedure. Such procedures are considered high-risk PCI (HR-PCI), where protective mechanical circulatory support (MCS) may be beneficial during the PCI procedure.<sup>3,4</sup> The intra-aortic balloon pump (IABP) and the percutaneous left ventricular assist device (pVAD) are the two most frequently used MCS devices for HR-PCI. The IABP chiefly serves to increase arterial pressures through counterpulsation, with limited improvement in cardiac output. In contrast, micro-axial rotary pumps, or pVADs, remove blood from the left ventricle and pump it into the ascending aorta, decreasing LV filling pressures and providing forward flow cardiac output.<sup>5</sup> The Impella 2.5 and CP heart pumps (Abiomed, Danvers, MA, USA) are the most commonly used pVADs for HR-PCI, with increasing use over the last decade.<sup>6</sup> Though the randomized PROTECT II trial showed equivalent outcomes with Impella and IABP-supported HR-PCI at 30 days (the primary endpoint),<sup>7</sup> there was a trend toward a late reduction in major adverse events (MAEs) for the Impella support group at 90 days, attaining significance when the analysis was conducted on the per-protocol population.<sup>8</sup> Postulated benefits of pVAD haemodynamic support are to provide operators time to perform more complete revascularization.<sup>9</sup>

Despite the potential benefits of pVAD support, bleeding and vascular complications remain a concern for elective use in HR-PCI, largely related to large bore vascular access. Such pVAD

related vascular complications are linked with significantly higher in-hospital mortality, length of stay, and cost,<sup>10</sup> limiting use of prophylactic pVAD circulatory support.

However, the observed rate of bleeding complications with Impella use has shown significant variability in published studies, which are largely retrospective and/or observational in nature. A recent analysis by Amin et al. including cardiogenic shock, a markedly higher risk population compared to HR-PCI, identified 2.5 times variability for Impella bleeding complications across centers.<sup>6</sup> Thus, the true risk of bleeding and vascular complications with Impella use remains incompletely defined.

### **Major bleeding and vascular complications with Impella-supported HR-PCI**

To evaluate the risk of major bleeding and vascular complications in Impella-supported HR-PCI, we performed a comprehensive literature review. The literature search was conducted in the PubMed and Cochrane databases in July 2020. The full literature search strategy is available in *Supplementary Table 1*. Our review was limited to studies reporting results of  $\geq 20$  patients,<sup>7,11-32</sup> in an attempt to capture studies from centres with more than casual experience with large bore access and Impella. We identified 23 such studies involving 3,466 patients undergoing elective or urgent HR-PCI, with Impella support initiated before or during PCI (*Table 1*).<sup>7,11-32</sup> The dataset comprises two prospective trials (the PROTECT I feasibility trial and the randomized PROTECT II pivotal trial), 9 retrospective, multicentre studies/registries, and 11 retrospective, single-centre studies. Major bleeding complications and major vascular complications were recorded per study report, though the reports were subject to varying definitions of major bleeding or vascular complications. Nearly half of the studies (10 studies) did not directly specify a bleeding complication definition. Such variability of definitions precluded a formal meta-analysis; thus, our review is qualitative, describing the published experience of bleeding and vascular complications consistent with real-world experience.

### **Major bleeding**

The median rate of major bleeding complications was 5.2% (range, 0–12.5%), with 22 of 23 studies contributing data. The rate of bleeding complications varied widely, likely due to variable definitions, incomplete data in some studies relative to site specific bleeding, inclusion of non-groin related bleeding events, and occasionally the inclusion of emergent, STEMI cases. Twelve studies (54.5%) reported major bleeding events without specifying the bleeding site.<sup>7,11,16,19-21,24-26,29-31</sup> Five studies (22.7%) reported that no major bleeding complications occurred.<sup>14,15,18,23,32</sup> The remaining five studies (22.7%) reported on bleeding complications and specified the bleeding site.<sup>12,17,22,27,28</sup> Of the five studies reporting bleeding complications and bleeding site, three studies reported that 100% of major bleeding complications were access related, with major bleeding complication rates of 2.7%, 3.3%, and 6.4% reported in these three studies.<sup>17,27,28</sup> One study reported that 80% of major bleeding complications were access related.<sup>22</sup> In the other study (a retrospective, gender-based analysis of 1053 patients treated in the multicentre cVAD registry), major bleeding complications occurred in 7.0% of patients, with 90.5% of bleeding events consisting of blood loss requiring transfusion.<sup>12</sup> The authors noted that low baseline haemoglobin levels and anaemia were mainly responsible for the elevated bleeding complication rate observed in females, as vascular complication rate was low (1.2%) and similar between genders.

### **Transfusion rates**

Transfusion rates showed the largest variation across studies, with a median rate of 5.4% (range, 0–34.3%) and 19 studies contributing data. In some studies, the number of patients requiring transfusion exceeded the number of reported bleeding complications, which likely reflected transfusions for baseline anaemia in some cases. Transfusion rates in the four studies in which the majority of transfusions were stated as being performed in the setting of baseline anaemia ranged from 5% to 34.3%.<sup>12,23,26,32</sup> Few studies included in our review reported on haemolysis (9 of 23 studies). Of these, three studies reported no haemolysis events, one reported only mild haemolysis not requiring treatment, and five studies reported haemolysis occurring in 1–2 patients, for overall haemolysis rates ranging from 0.2% to 3.7%. Haemolysis

requiring transfusion did not contribute to meaningfully to overall transfusion rates in most cases (*Table 2*).

### **Vascular complications**

Median rate of major vascular complications was 2.6% (range, 0–8.3%), with 15 of the 19 studies contributing data reporting a vascular complication rate <5%. The rate of vascular complications did not vary as widely as bleeding complication rates: this finding likely reflects the fact that major bleeding complications may stem from non-access as well as access-related causes, whereas vascular complications by definition are more specific.

### **Trends in bleeding and vascular complications over time**

Bleeding complications over time demonstrated that the variability in bleeding risk seen across centres has not changed meaningfully over the last fifteen years (*Figure 1*). Given the broad scope of bleeding complications (comprising both access and non-access related bleeding during PCI), often complicated by pre-existing anaemia and the inclusion of some urgent HR-PCI patient populations, this variability is not surprising. Likewise, many series reported relatively low numbers of cases over extended time periods, suggesting that any advantages of increased operator skill, using best practices accrued through increasing experience, could not be ascertained. While we attempted to focus on higher volume reports ( $\geq 20$  patients) to provide “best practice” results, eliminating “occasional users”, even in larger studies it is impossible to identify the extent to which specific operators or teams were involved in a series of cases, minimizing our ability to assess whether any potential learning curve with the large bore Impella procedure is driving bleeding complication rates. Thus, low yearly volumes may obscure the ability to ascertain whether improvements in outcomes over time occur with increased operator and institutional for large bore access and supported HR-PCI experience, as has been reported for trans-aortic valve repair (TAVR).<sup>33,34</sup> Rate of vascular complications remained consistently low over time (*Figure 2*). Transfusion rates suggest a downward trend over time (*Figure 3*).

### **Impact of access and non-access bleeding complications on clinical outcomes**

A significant limitation in published studies on HR-PCI is the relative rarity of studies identifying the specific aetiology of bleeding complications – whether access related or GI bleeding, etc. In a large CathPCI registry analysis of bleeding in a largely elective-urgent, not specifically high-risk PCI patient population, Rao et al. reported a similar overall bleeding rate of 5.8%, and found that 32% of bleeding events had a specified site, with a further 44.6% due to haemoglobin decrease and 21.8% due to blood transfusions.<sup>35</sup>

The prognostic relationship of PCI bleeding complications with mortality varies greatly depending on the site of bleeding. A large meta-analysis of PCI studies (primarily acute myocardial infarction patient populations) specifying the site of bleeding complications found that, while both access and non-access related bleeding complications were linked with an increased risk for mortality, the risk ratio (RR) for non-access site bleeding was considerably higher than with access site bleeding (4.06 and 1.71 RRs, respectively).<sup>36</sup> To our knowledge, there has been no comprehensive review of access vs non-access related bleeding complications and their respective prognostic values in an exclusively elective-urgent HR-PCI population with MCS support. Our review identified the difficulties in conducting such a review from the current literature, as a majority of studies did not specify bleeding site.

Bleeding definition used also significantly impacts the prognostic value of reported bleeding events, and in our review, varied widely across published studies. Often, major bleeding definition was not specified at all. A meta-analysis of PCI studies (STEMI and elective patient populations) encompassing several different bleeding definitions found that, depending on the definition used, the mortality risk from a major bleeding event ranged from a 1.5 to 6.7 times increase.<sup>37</sup>

### **Factors impacting bleeding complications in Impella-supported HR-PCI**

An observed increase in femoral access complications with PCI in recent years may be due in large part to the swift uptake of radial access for conventional PCI procedures by many

operators.<sup>38</sup> This “Campeaux Paradox” has occurred due to operators having fewer femoral access cases, with a subsequent loss of femoral skills. Though radial access for PCI has been associated with reduced complications compared to femoral access in several prospective studies,<sup>39</sup> there will always be a requirement for femoral access in some cases with challenging anatomy, necessitating that operators maintain femoral skills, both for PCI access and also for large bore sheath procedures such as TAVR and pVAD placement. There is also a potential learning curve for large bore access procedures, both on the operator level but also involving team experience with large bore procedures and effective management of access complications. In the USpella registry, Cohen et al. identified declining transfusion rates of 12.2%, 7.4%, and 6.1% in patients treated in the years 2009, 2010, and 2011, respectively.<sup>21</sup> The authors suggested that a learning curve with large access closure techniques was potentially responsible for the decreasing transfusion rate over time.

In multiple studies identified in this review, all or a majority of transfusions were to aid clinical recovery due to baseline anemia.<sup>12,23,26,32</sup> Low baseline haemoglobin levels were one of 10 variables included in a validated bleeding risk model developed by Rao et al. to delineate high bleeding risk (HBR) in patients up to 72 hours after undergoing PCI.<sup>35</sup> While some factors were related to clinical circumstances such as acute myocardial infarction and/or shock, others were patient-related and likely risk factors related to Impella procedures including female gender, age >70 years, renal failure, diabetes, and high BMI. Thus, bleeding/transfusion risk is a composite of access site and clinical patient features. Those patients deemed to be HBR merit careful consideration of whether MCS is necessary to support the HR-PCI procedure. Recently emerging technologies aimed to reduce vascular complications with large bore access may ameliorate the risk of access site bleeding and vascular complications in HBR patients, and are discussed in a later section.

### **Risk-benefit assessment of elective Impella support**

Considerations for MCS haemodynamic support vary by severity and complexity of anatomic coronary disease, overall patient clinical risk, and baseline haemodynamic stability including

overall left ventricular function, further modulated by operator–estimated patient risk for haemodynamic collapse during PCI. While operator experience is often considered a factor, not all studies have shown an outcome benefit for high operator experience.<sup>40</sup> Bleeding and vascular complications remain an important consideration related to MCS support for HR-PCI.

An important consideration for operators is the outcome risk when managing a patient with acute haemodynamic collapse during PCI, most often secondary to a complication. A recent cVAD registry analysis of patients undergoing HR-PCI with Impella either pre-procedure (prophylactic) or as bailout showed a striking risk for the bailout group.<sup>41</sup> Specifically, those patients treated with bailout as opposed to prophylactic Impella support during HR-PCI had significantly higher in-hospital mortality (49.1% vs 4.3%).<sup>41</sup> What remains unknown is the percentage of patients undergoing unsupported HR-PCI who ultimately experience severe haemodynamic instability requiring bailout MCS. Thus, in the absence of Level 1 evidence and specific guidelines for pVAD support during HR-PCI, variation in approaches further add to the difficulty in analysing overall procedural risk as well as bleeding risk.

#### **Limitations of clinical dataset and future directions**

In our review, the site of bleeding events is seldom specified. Importantly, reported bleeding complications not only reflect complications due to large bore Impella access, but other access sites such as PCI access, as well as GI bleeding, transfusions to aid clinical recovery, anticoagulation practices (i.e., failure to titrate total heparin administration for the Impella purge solution), HBR patients, or other, unspecified causes.

In recent years, there has been significant focus on developing improved techniques for access site and anticoagulation management, as well as appropriate closure techniques, all potentially limiting access site bleeding risk. Few studies have been conducted exclusively in the last 5 years on Impella-supported HR-PCI with reported outcomes on complications observed; in fact, no studies of  $\geq 20$  patients appear to have been conducted exclusively in the last two

years. This limits our ability to assess the impact of emerging solutions for large bore access strategy on bleeding complication rates.

### **Evolving solutions**

In an attempt to reduce bleeding risks, a variety of new techniques continue to be introduced. Because the number of vascular access sites required for a complex procedure increases the risk of a vascular event, a newly introduced single access Impella technique has the potential to reduce access site complications for Impella-supported HR-PCI by eliminating the need for a separate PCI access site.<sup>42</sup> While an initial report on outcomes with this technique is encouraging, larger data is needed to assess its safety and efficacy.<sup>42</sup> Recent reports suggest that the use of routine ultrasound guidance for large bore femoral access may reduce vascular and bleeding complications.<sup>43,44</sup> Another development for large bore procedures is the recent approval of the MANTA VCD (Teleflex, Morrisville, NC, USA), a closure device specifically designed for 10–20 Fr large bore procedures, though predominantly evaluated in TAVR studies published to date.<sup>45-48</sup> While new techniques and devices are encouraging, larger studies will be required to both identify and confirm the optimal strategies to ultimately reduce bleeding and vascular complications associated with large bore access for haemodynamic support in HR-PCI.

### **Conclusions**

Bleeding and vascular complications adversely affect clinical outcomes after Impella-supported HR-PCI. Rates of major bleeding complications have shown wide variation over the last 15 years, underlining the importance of recognizing the risks related to large bore sheath procedures. Transfusion rates appear to have decreased over time, whereas occurrence of major vascular complications has remained relatively constant (<5% in most studies over the last 15 years). Thus, patient selection for protected HR-PCI should involve consideration of HBR factors and utilizing currently accepted, patient-specific, bleeding avoidance strategies, as well as optimal vascular access management to minimize bleeding and vascular risk when Impella is used for HR-PCI.

## References

1. Kataruka A, Maynard CC, Kearney KE, et al. Temporal Trends in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting: Insights From the Washington Cardiac Care Outcomes Assessment Program. *J Am Heart Assoc.* 2020;9(11):e015317.
2. Waldo SW, Secemsky EA, O'Brien C, et al. Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention. *Circulation.* 2014;130(25):2295-2301.
3. Bass TA. High-Risk Percutaneous Coronary Interventions in Modern Day Clinical Practice: Current Concepts and Challenges. *Circ Cardiovasc Interv.* 2015;8(12):e003405.
4. Myat A, Patel N, Tehrani S, Banning AP, Redwood SR, Bhatt DL. Percutaneous circulatory assist devices for high-risk coronary intervention. *JACC Cardiovasc Interv.* 2015;8(2):229-244.
5. Burkhoff D, Sayer G, Doshi D, Uriel N. Hemodynamics of Mechanical Circulatory Support. *J Am Coll Cardiol.* 2015;66(23):2663-2674.
6. Amin AP, Spertus JA, Curtis JP, et al. The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support. *Circulation.* 2020;141(4):273-284.
7. O'Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. *Circulation.* 2012;126(14):1717-1727.
8. Dangas GD, Kini AS, Sharma SK, et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). *Am J Cardiol.* 2014;113(2):222-228.
9. Vetrovec GW. Hemodynamic Support Devices for Shock and High-Risk PCI: When and Which One. *Curr Cardiol Rep.* 2017;19(10):100.

10. Patel N, Sharma A, Dalia T, et al. Vascular complications associated with percutaneous left ventricular assist device placement: A 10-year US perspective. *Catheter Cardiovasc Interv.* 2020;95(2):309-316.
11. Alasnag MA, Gardi DO, Elder M, et al. Use of the Impella 2.5 for prophylactic circulatory support during elective high-risk percutaneous coronary intervention. *Cardiovasc Revasc Med.* 2011;12(5):299-303.
12. Alraies MC, Kaki A, Kajy M, et al. Sex-related difference in the use of percutaneous left ventricular assist device in patients undergoing complex high-risk percutaneous coronary intervention: Insight from the cVAD registry. *Catheter Cardiovasc Interv.* 2019.
13. Al-Rashid F, Mahabadi AA, Johannsen L, et al. Impact of left-ventricular end-diastolic pressure as a predictor of periprocedural hemodynamic deterioration in patients undergoing Impella supported high-risk percutaneous coronary interventions. *Int J Cardiol Heart Vasc.* 2020;26:100445.
14. Amponsah MK, Tayal R, Khakwani Z, Sinclair M, Wasty N. Safety and Efficacy of a Novel "Hybrid Closure" Technique in Large-Bore Arteriotomies. *Int J Angiol.* 2017;26(2):116-120.
15. Anusionwu O, Fischman D, Cheriya P. The Duration of Impella 2.5 Circulatory Support and Length of Hospital Stay of Patients Undergoing High-risk Percutaneous Coronary Interventions. *Cardiol Res.* 2012;3(4):154-157.
16. Azzalini L, Johal GS, Baber U, et al. Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry. *Catheter Cardiovasc Interv.* 2020.
17. Baumann S, Werner N, Al-Rashid F, et al. Six months follow-up of protected high-risk percutaneous coronary intervention with the microaxial Impella pump: results from the German Impella registry. *Coron Artery Dis.* 2020;31(3):237-242.
18. Becher T, Baumann S, Eder F, et al. Comparison of peri and post-procedural complications in patients undergoing revascularisation of coronary artery multivessel disease by coronary artery bypass grafting or protected percutaneous coronary

- intervention with the Impella 2.5 device. *Eur Heart J Acute Cardiovasc Care*. 2019;8(4):360-368.
19. Burzotta F, Russo G, Ribichini F, et al. Long-Term Outcomes of Extent of Revascularization in Complex High Risk and Indicated Patients Undergoing Impella-Protected Percutaneous Coronary Intervention: Report from the Roma-Verona Registry. *J Interv Cardiol*. 2019;2019:5243913.
  20. Chieffo A, Ancona MB, Burzotta F, et al. Observational multicentre registry of patients treated with IMPella mechanical circulatory support device in Italy: the IMP-IT registry. *EuroIntervention*. 2020;15(15):e1343-e1350.
  21. Cohen MG, Matthews R, Maini B, et al. Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience. *Am Heart J*. 2015;170(5):872-879.
  22. Danek BA, Basir MB, O'Neill WW, et al. Mechanical Circulatory Support in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter U.S. Registry. *J Invasive Cardiol*. 2018;30(3):81-87.
  23. Dixon SR, Henriques JP, Mauri L, et al. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. *JACC Cardiovasc Interv*. 2009;2(2):91-96.
  24. Doshi R, Singh A, Jauhar R, Meraj PM. Gender difference with the use of percutaneous left ventricular assist device in patients undergoing complex high-risk percutaneous coronary intervention: From pVAD Working Group. *Eur Heart J Acute Cardiovasc Care*. 2019;8(4):369-378.
  25. Ferreiro JL, Gómez-Hospital JA, Cequier Á R, et al. Use of Impella Recover LP 2.5 in elective high risk percutaneous coronary intervention. *Int J Cardiol*. 2010;145(2):235-237.
  26. Iliodromitis KE, Kahlert P, Plicht B, et al. High-risk PCI in acute coronary syndromes with Impella LP 2.5 device support. *Int J Cardiol*. 2011;153(1):59-63.

27. Johannsen L, Mahabadi AA, Totzeck M, et al. Access site complications following Impella-supported high-risk percutaneous coronary interventions. *Sci Rep*. 2019;9(1):17844.
28. Kovacic JC, Nguyen HT, Karajgikar R, Sharma SK, Kini AS. The Impella Recover 2.5 and TandemHeart ventricular assist devices are safe and associated with equivalent clinical outcomes in patients undergoing high-risk percutaneous coronary intervention. *Catheter Cardiovasc Interv*. 2013;82(1):E28-37.
29. Riley RF, McCabe JM, Kalra S, et al. Impella-assisted chronic total occlusion percutaneous coronary interventions: A multicenter retrospective analysis. *Catheter Cardiovasc Interv*. 2018;92(7):1261-1267.
30. Russo G, Burzotta F, D'Amario D, et al. Hemodynamics and its predictors during Impella-protected PCI in high risk patients with reduced ejection fraction. *Int J Cardiol*. 2019;274:221-225.
31. Sjauw KD, Konorza T, Erbel R, et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. *J Am Coll Cardiol*. 2009;54(25):2430-2434.
32. Venugopal V, Spiro J, Zaphiriou A, et al. Percutaneous Mechanical Ventricular Support in Acute Cardiac Care: A UK Quaternary Centre Experience Using 2.5L, 3.8L and 5.0L Impella Catheters. *Cardiol Ther*. 2015;4(1):47-58.
33. Russo MJ, McCabe JM, Thourani VH, et al. Case Volume and Outcomes After TAVR With Balloon-Expandable Prostheses: Insights From TVT Registry. *J Am Coll Cardiol*. 2019;73(4):427-440.
34. Wassef AWA, Rodes-Cabau J, Liu Y, et al. The Learning Curve and Annual Procedure Volume Standards for Optimum Outcomes of Transcatheter Aortic Valve Replacement: Findings From an International Registry. *JACC Cardiovasc Interv*. 2018;11(17):1669-1679.
35. Rao SV, McCoy LA, Spertus JA, et al. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National

- Cardiovascular Data Registry CathPCI Registry. *JACC Cardiovasc Interv.* 2013;6(9):897-904.
36. Kwok CS, Khan MA, Rao SV, et al. Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis. *Circ Cardiovasc Interv.* 2015;8(4).
  37. Kwok CS, Rao SV, Myint PK, et al. Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis. *Open Heart.* 2014;1(1):e000021.
  38. Azzalini L, Tosin K, Chabot-Blanchet M, et al. The Benefits Conferred by Radial Access for Cardiac Catheterization Are Offset by a Paradoxical Increase in the Rate of Vascular Access Site Complications With Femoral Access: The Campeau Radial Paradox. *JACC Cardiovasc Interv.* 2015;8(14):1854-1864.
  39. Valgimigli M, Gagnor A, Calabro P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. *Lancet.* 2015;385(9986):2465-2476.
  40. Kinnaird T, Gallagher S, Spratt JC, et al. Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome? *Am Heart J.* 2020;222:15-25.
  41. O'Neill W, Moses JW, Popma JJ. Outcomes of Impella use as prophylactic versus bailout strategy in patients undergoing non-emergent percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2020;95: S54-S55.
  42. Wollmuth J, Korngold E, Croce K, Pinto DS. The Single-access for Hi-risk PCI (SHiP) technique. *Catheter Cardiovasc Interv.* 2020;96(1):114-116.
  43. Potluri SP, Hamandi M, Basra SS, et al. Comparison of Frequency of Vascular Complications With Ultrasound-Guided Versus Fluoroscopic Roadmap-Guided Femoral Arterial Access in Patients Who Underwent Transcatheter Aortic Valve Implantation. *Am J Cardiol.* 2020;132:93-99.

44. Vincent F, Spillemaecker H, Kyheng M, et al. Ultrasound Guidance to Reduce Vascular and Bleeding Complications of Percutaneous Transfemoral Transcatheter Aortic Valve Replacement: A Propensity Score-Matched Comparison. *J Am Heart Assoc.* 2020;9(6):e014916.
45. Biancari F, Romppanen H, Savontaus M, et al. MANTA versus ProGlide vascular closure devices in transfemoral transcatheter aortic valve implantation. *Int J Cardiol.* 2018;263:29-31.
46. De Palma R, Settergren M, Ruck A, Linder R, Saleh N. Impact of percutaneous femoral arteriotomy closure using the MANTA(TM) device on vascular and bleeding complications after transcatheter aortic valve replacement. *Catheter Cardiovasc Interv.* 2018;92(5):954-961.
47. Gheorghe L, Brouwer J, Mathijssen H, et al. Early Outcomes After Percutaneous Closure of Access Site in Transfemoral Transcatheter Valve Implantation Using the Novel Vascular Closure Device Collagen Plug-Based MANTA. *Am J Cardiol.* 2019;124(8):1265-1271.
48. Moriyama N, Lindstrom L, Laine M. Propensity-matched comparison of vascular closure devices after transcatheter aortic valve replacement using MANTA versus ProGlide. *EuroIntervention.* 2019;14(15):e1558-e1565.

## Figure Legends


**Figure 1.** Major bleeding complications as reported across Impella-supported HR-PCI studies conducted from 2004 to 2018, with studies ordered from earliest year of study enrollment to latest. One study not including years of enrollment (Baumann et al) is excluded. NR=not reported.



**Figure 2.** Major vascular complications reported across Impella studies by ascending year.



**Figure 3.** Rate of transfusions reported across Impella studies by ascending year.



**Table 1.** Study design and patient population characteristics in studies  $\geq 20$  patients undergoing Impella-supported HRPCI

Ref	Study Design	Sample Size (Treatment Dates)	Elective/Urgent HR-PCI	Major bleeding definition <sup>a</sup>	Definition provided in Methods
Al-Rashid (2020)	Retrospective, single-center study (Germany)	64 patients (2017-2018)	Elective or urgent (including STEMI)	1	N
Johannsen (2019)	Retrospective, single-center study (Germany)	61 patients (2016-2018)	Elective or urgent (including STEMI; 46% ACS)	2	Y
Becher (2017)	Retrospective, single-center study (Germany)	54 patients (26 Impella; 2015-2016)	Elective or urgent (15% STEMI)	3	N
Riley (2018)	Retrospective, multicenter CTO-PCI study (5 centers, US)	57 patients (2013-2017)	100% elective	2	Y
Russo (2019)	Retrospective, multicenter study (2 centers, Italy)	37 patients (2013-2016)	100% elective (no AMI within 24 hr)	2	N
Amponsah (2017)	Retrospective, single-center study (US)	40 patients (2013-2014)	NR	1	Y
Danek (2018)	Retrospective, multicenter PROGRESS-CTO registry (12 centers, US)	1598 patients (50 Impella 2.5/CP; 2012-2017)	18% urgent (Impella initiated during PCI), 82% elective	3	Y

Doshi (2019)	Retrospective, multicenter study (2 centers, US)	160 patients (2011-2016)	Elective or urgent (27% STEMI)	2	Y
Azzalini (2020)	Retrospective, single-center study (US)	250 patients (2009-2018)	Elective or urgent (no STEMI)	2	Y
Venugopal (2015)	Retrospective, single-center registry (UK)	49 patients (45 HRPCI; 2008-2014)	62% urgent, 38% elective	1	N
Alasnag (2011)	Retrospective, single-center study (US)	60 patients (2008-2010)	100% elective	1	N
Anusionwu (2012)	Retrospective, single-center study (US)	25 patients (2008-2009)	NR	1	N
Burzotta (2019)	Retrospective, multicenter Roma- Verona registry (2 centers, Italy)	86 patients (2007-2016)	100% elective (no AMI within 24 hr)	3	Y
Alraies (2019)	Retrospective, multicenter CVAD registry (US, Canada, Europe)	1,053 patients (2007-2015)	Elective or urgent	3	Y
Cohen (2015)	Retrospective, multicenter USpella registry (49 centers, US & Canada)	637 patients (USpella patients; 2007- 2013)	Elective or urgent	3	N

Cohen (2015) / O'Neill (2012)	Multicenter PROTECT II RCT (112 centers, US, Canada, and Europe) <sup>b</sup>	216 patients (Impella arm of PROTECT II, 2007-2010)	Elective or urgent (no recent MI)	3	N
Iliodromitis (2011)	Retrospective, single-center study (Germany)	38 patients (2006-2009)	100% urgent (Unstable angina or NSTEMI)	3	Y
Ferreiro (2010)	Retrospective, single-center study (Spain)	27 patients (2006-2008)	100% elective	3	Y
Dixon (2009)	Prospective, multicenter PROTECT I study (US & Netherlands)	20 patients (2006-2007)	Elective or urgent (no STEMI within 7d or CA within 24 hr)	1	N
Kovacic (2013)	Retrospective, single-center study (US)	68 patients (36 Impella; 2005-2010)	100% elective	2	Y
Chieffo (2020)	Retrospective, multicenter IMP-IT registry (17 centers, Italy)	406 patients (177 Impella HRPCI; 2004-2018)	Elective or urgent (32% Impella placement during PCI, 0.5% after PCI)	2	Y
Sjauw (2009)	Retrospective, multicenter Europella registry (Europe)	144 patients (2004-2007)	100% elective (no STEMI within 48 hr)	3	Y

Baumann (2020)	Retrospective, multicenter German Impella registry (6 centers, Germany)	157 patients (unknown years)	Elective or “semi-elective”	1	N
-------------------	---	------------------------------	-----------------------------	---	---

AMI, acute myocardial infarction; CA, cardiac arrest; CS, cardiogenic shock; NR, not reported; NSTEMI, Non-ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

<sup>a</sup> Major bleeding definitions in the included studies were considered to fall into three separate definition groups, identified with the numbers 1-3.

- 1) No major bleeding definition provided, or definition was incomplete (i.e., listing a variety of vascular complication event types and transfusion, but not specifying an interventional threshold for major bleeding
- 2) Major bleeding defined as bleeding event requiring transfusion, surgery, or any unplanned procedure
- 3) Major bleeding defined as bleeding event requiring transfusion or surgery

<sup>b</sup> Both Cohen (2015) and O’Neill (2012) publications are listed for the PROTECT II trial. The Cohen publication is the primary report of study outcomes; however, it did not detail bleeding and vascular complications, which were provided in the comparative analysis conducted by Cohen et al.

**Table 2.** Periprocedural bleeding and vascular complications in studies  $\geq 20$  patients undergoing Impella-supported HRPCI

Ref	Major Vascular Complications	Major Bleeding Complications	Access-Related	Transfusion Only	Minor Vascular / Bleeding Complications
Al-Rashid (2020)	3.1% (2/64)	NR	--	NR	NR
Johannsen (2019)	8.2% (5/61; 2 inguinal hematoma, 3 access site bleeding [1 requiring transfusion])	3.3% (2/61; bleeding from access site with hgb drop $\geq 3$ g/dl [1 requiring transfusion])	100%	1.6% (1/61)	36.1% (22/61; 95% superficial hematoma, no treatment required)
Becher (2017)	0% (0/54)	0% (0/26)	None	0% (0/26)	NR
Riley (2018)	5.3% (3/57; all vascular injury requiring intervention)	3.5% (2/57; BARC 3/5)	NR	NR	NR
Russo (2019)	2.7% (1/37; distal embolization requiring urgent angioplasty)	5.4% (2/37; all transfusions)	NR	5.4% (2/37)	NR
Amponsah (2017)	0% (0/40)	0% (0/40)	None	0% (0/40)	5.0% (2/40; 1 patient had Mynx rupture after Perclose, 1 had Perclose failure)

Danek (2018)	NR	10.0% (5/50; Impella 2.5: 21.1% [4/19]; Impella CP: 3.2% [1/31])	80% access-related	NR	8.0% (4/50; vascular access site bleeding; Impella 2.5: 15.8% [3/19]; Impella CP: 3.2% [1/31])
Doshi (2019)	NR	5.0% (8/160; bleeding within 72 hours)	NR	3.1% (5/160)	NR
Azzalini (2020)	NR	6.8% (17/250)	NR <sup>a</sup>	11.2% (28/250)	NR
Venugopal (2015)	0% (0/45)	0% (0/45)	None	4.4% (2/45; transfusions to aid clinical recovery for pre-existing anemia [no evidence of bleeding or fall in Hgb levels])	NR
Alasnag (2011)	0% (0/60)	10% (6/60; all transfusions)	NR	10% (6/60)	8.3% (5/60; groin hematomas that resolved without residual effects)
Anusionwu (2012)	NR	0% (0/25)	None	0% (0/25)	8.0% (2/25; groin hematoma, resolved with manual compression)
Burzotta (2019)	0% (0/86)	4.7% (4/86; 4 BARC 3 events with 3 requiring transfusion)	NR	3.5% (3/86)	11.6% (9/86, 6 BARC 1 hematomas, 2 BARC 2 PTA to

					facilitate haemostasis, 2 minor vascular complications [1 access site vascular injury managed conservatively, 1 distal embolization / ALI event])
Alraies (2019)	1.2% (13/1053; vascular complications requiring surgery)	7.0% (74/1053; 67 required transfusion, 7 required surgery) <sup>c</sup>	Primarily anemia related <sup>b</sup>	6.4% (67/1053) <sup>b</sup>	6.0% (63/1053; 40 hematoma, 23 vascular complications not requiring surgery [likely overlap between these two counts])
Cohen (2015)	2.5% (16/637; vascular complications requiring surgery)	11% (70/637; all transfusions)	NR	11.0% (70/637) <sup>c</sup>	5.2% (33/637; vascular complications not requiring surgery)
Cohen (2015) / O'Neill (2012)	1.4% (3/216; vascular complications requiring surgery)	12.5% (27/216; all transfusions)	NR	12.5% (27/216) <sup>c</sup>	9.3% (20/216; vascular complications not requiring surgery)
Iliodromitis (2011)	2.6% (1/38; pseudoaneurysm requiring prolonged hospitalization and pressure badge)	5.3% (2/38)	NR	34.3% (13/38; 11 due to pre-existing anemia for additional blood supply, 2 due to bleeding complications)	31.6% (12/38; 6 minor bleeding, 6 femoral hematoma not requiring transfusion)

Ferreiro (2010)	3.7% (1/27; limb ischemia requiring surgery)	7.4% (2/27; 1 specified as intracranial bleeding 8 hours post Impella removal)	1 not specified, 1 non-access	3.7% (1/27) <sup>d</sup>	14.8% (4/27; 2 limb ischemia managed medically and not classed as severe, 2 minor bleeding)
Dixon (2009)	0% (0/20)	0% (0/20)	None	10.0% (2/20; 1 due to baseline anemia, 1 due to hematuria secondary to bladder cancer)	40.0% (8/20; hematoma, none requiring transfusion or vascular repair)
Kovacic (2013)	8.3% (3/36; 1 pseudoaneurysm requiring thrombin injection, 1 femoral artery occlusion, treated percutaneously, 1 hematoma requiring transfusion)	2.7% (1/36; hematoma requiring transfusion)	100%	2.7% (1/36)	8.3% (3/36; 2 small hematoma and 1 large hematoma, none requiring transfusion)
Chieffo (2020)	2.8%(5/177; 5 device-related complications requiring intervention [5 limb ischemia occurred, presumably all requiring intervention] <sup>c</sup>	5.1% (8/177)	NR	NR	7.9% (14/177; access site bleeding not classified as severe)

Sjauw (2009)	4.0% (6/144; spurious aneurysm, fistula)	6.3% (9/144; 8 required transfusion, 1 required surgery)	NR	6.25% (9/144) <sup>e</sup>	NR
Bauman (2020)	6.4% (10/157; 3 peripheral leg ischemia, 2 aneurysm spurium, 2 dissection, 2 thrombus, 1 embolism)	6.4% (10/157; access site bleeding requiring transfusion)	100%	6.4% (10/157)	NR

Hgb, haemoglobin; NR, not reported.

Minor vascular/bleeding complications are per study reporting.

<sup>a</sup> Azzalini et al. reported that there was higher access-related bleeding in patients with Impella-supported HRPCI vs those with no MCS; however, there was no quantification of this or description of bleeding events, so it is unknown what percentage of bleeding complications were related to access.

<sup>b</sup> The authors state that most transfusions were due to patient baseline condition/anaemia; however, this was not quantified within the reported number of bleeding complications / transfusions. Therefore, the percentage listed with major bleeding (7%; 74 patients including 67 with transfusion) includes a significant proportion with transfusion for baseline anaemia.

<sup>c</sup> In the PROTECT II and USpella comparative study, haemolysis occurred in 1 USpella patient (0.2%) and 2 PROTECT II patients (0.9%). Though Cohen et al. did not report whether haemolysis events required transfusion, if all required transfusion, this would constitute 1.4% and 7.4% of all reported transfusions being performed in the setting of haemolysis.

<sup>d</sup> One patient (3.7%) experienced haemolysis requiring transfusion in this study; this constituted the only transfusion reported.

<sup>e</sup> One patient (0.7%) experienced haemolysis requiring transfusion; this constituted 1 of 9 (11.1%) of transfusions performed in the study.